SAKAR

Sakar Healthcare Share Price

 

 

Start SIP in SAKAR

Start SIP
Sakar Healthcare live price: ₹518.75. It opened at ₹560 vs previous close ₹557; intraday high/low: ₹560/₹515. The 50 & 200 DMA stand at ₹467.76/₹393.13.

Sakar Healthcare Performance

  • Low
  • ₹515
  • High
  • ₹560
  • 52 Week Low
  • ₹210
  • 52 Week High
  • ₹570
  • Open Price₹560
  • Previous Close₹557
  • Volume74,804
  • 50 DMA₹467.76
  • 100 DMA₹431.35
  • 200 DMA₹393.13

Investment Returns

  • Over 1 Month + 16.12%
  • Over 3 Month + 22.82%
  • Over 6 Month + 55.17%
  • Over 1 Year + 117.27%

Smart Investing Starts Here Start SIP with Sakar Healthcare for Steady Growth!

Invest Now

Sakar Healthcare Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 45.8
  • PEG Ratio
  • 0.7
  • Market Cap Cr
  • 1,154
  • P/B Ratio
  • 3.7
  • Average True Range
  • 34.56
  • EPS
  • 11.34
  • Dividend Yield
  • 0
  • MACD Signal
  • 26.93
  • RSI
  • 55.8
  • MFI
  • 82.55

Sakar Healthcare Financials

Sakar Healthcare Technicals

EMA & SMA

Current Price
₹518.75
-38.05 (-6.83%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹509.83
  • 50 Day
  • ₹467.76
  • 100 Day
  • ₹431.35
  • 200 Day
  • ₹393.13

Resistance and Support

531.23 Pivot Speed
  • R3 592.42
  • R2 576.18
  • R1 547.47
  • S1 502.52
  • S2 486.28
  • S3 457.57

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sakar Healthcare has an operating revenue of Rs. 230.88 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 12% is healthy, ROE of 6% is fair but needs improvement. The company has a reasonable debt to equity of 19%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 24% and 46% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 25% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 63 which is a FAIR score but needs to improve its earnings, a RS Rating of 96 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 45 indicates it belongs to a fair industry group of Medical-Ethical Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sakar Healthcare Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-05 Quarterly Results & Others To consider other business matters.
2025-11-07 Quarterly Results & Others To consider other business matters.
2025-07-25 Quarterly Results & Others To consider other business matters.
2025-05-15 Audited results
2025-02-08 Quarterly Results

Sakar Healthcare F&O

Sakar Healthcare Shareholding Pattern

52.86%
13.05%
16.59%
17.5%

About Sakar Healthcare

  • NSE Symbol
  • SAKAR
  • BSE Symbol
  • Chairman & Managing Director
  • Mr. Sanjay S Shah
  • ISIN
  • INE732S01012

Similar Stocks to Sakar Healthcare

Sakar Healthcare FAQs

Sakar Healthcare share price is ₹518 As on 14 March, 2026 | 17:24

The Market Cap of Sakar Healthcare is ₹1154.2 Cr As on 14 March, 2026 | 17:24

The P/E ratio of Sakar Healthcare is 45.8 As on 14 March, 2026 | 17:24

The PB ratio of Sakar Healthcare is 3.7 As on 14 March, 2026 | 17:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23